13:41 IST
BSE
Other Announcement
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Sun Pharma Advanced Research Company Ltd
- Share price
- ₹196.73
- Market cap
- ₹6,384 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 4.0×Sector 47.4×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.90%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 3Promoter Reclassification 2Annual General Meeting 2Management Change 1Financial Results 1Business Update 1Board Meeting Date 1Annual Report 1
Time
12 announcements with these filters
16:44 IST
NSE
Promoter Reclassification
Sun Pharma Advanced Research Company Promoter Reclassification
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.
19:39 IST
NSE
Annual General Meeting
Sun Pharma Advanced Research Company Annual General Meeting
SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.
14:56 IST
BSE
Other Announcement
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms zero deviation in utilizing proceeds from its Rs. 599.98 Crore warrant issue.
- Value
- ₹600.0 Cr
13:29 IST
BSE
Financial Results
Sun Pharma Advanced Research Company Q1 FY27 Results: Net Loss of ₹20.8 Cr, Loss Narrows
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹39.9 Cr (+315.6% YoY) and a net loss of ₹20.8 Cr for Q1 FY27.
- Key figure
- Net loss ₹20.8 Cr
14:56 IST
BSE
Board Meeting Date
Sun Pharma Advanced Research Company Board Meeting Date
Sun Pharma Advanced Research Company Limited scheduled a Board Meeting for August 10, 2026. The meeting will consider unaudited financial results for the period ended June 2026.
18:15 IST
NSE
Promoter Reclassification
Sun Pharma Advanced Research Company Promoter Reclassification
Sun Pharma Advanced Research Company has received requests from certain Promoter Group members to reclassify their status to the 'Public' category.
14:15 IST
BSE
Other Announcement
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details equity holdings across promoter and public categories.
20:57 IST
BSE
Business Update
Sun Pharma Advanced Research Company Business Update
Sun Pharma Advanced Research Company submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report detailing ESG initiatives forms part of the Annual Report.
20:49 IST
BSE
Annual General Meeting
Sun Pharma Advanced Research Company Annual General Meeting
SPARC scheduled its 21st AGM for August 10, 2026, via video conference. Agenda includes adopting FY26 financials and appointing Anil Kumar Raghavan as MD and CEO.
20:45 IST
NSE
Annual Report
Sun Pharma Advanced Research Company Annual Report
Sun Pharma Advanced Research Company submitted its FY 2025-26 Annual Report. The 21st AGM is scheduled for August 10, 2026, via video conferencing.
17:37 IST
NSE
Management Change
Sun Pharma Advanced Research Company Management Change
SPARC appointed Anil Raghavan as Managing Director and CEO effective August 11, 2026. Dr. Rajamannar Thennati will retire from the Board on August 10, 2026.